{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:29:59Z","timestamp":1793089799159,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-022-00805-4","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T03:04:06Z","timestamp":1646276646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma"],"prefix":"10.1007","author":[{"given":"Hu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Ping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-9814","authenticated-orcid":false,"given":"Guo-Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"issue":"25","key":"805_CR1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"10","key":"805_CR2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","volume":"101","author":"A Perry","year":"2016","unstructured":"Perry A, Diebold J, Nathwani B, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016;101(10):1244\u201350.","journal-title":"Haematologica"},{"issue":"2","key":"805_CR3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-015-2543-4","volume":"95","author":"A Perry","year":"2016","unstructured":"Perry A, Diebold J, Nathwani B, et al. Non-Hodgkin lymphoma in the far east: review of 730 cases from the international non-Hodgkin lymphoma classification project. Ann Hematol. 2016;95(2):245\u201351.","journal-title":"Ann Hematol"},{"issue":"3","key":"805_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429\u201334.","journal-title":"Am J Clin Pathol"},{"issue":"20","key":"805_CR5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"S Swerdlow","year":"2016","unstructured":"Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"805_CR6","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","volume":"4","author":"R Briski","year":"2014","unstructured":"Briski R, Feldman A, Bailey N, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214.","journal-title":"Blood Cancer J."},{"key":"805_CR7","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"A Abouyabis","year":"2011","unstructured":"Abouyabis A, Shenoy P, Sinha R, Flowers C, Lechowicz M. A Systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell Lymphoma. ISRN Hematol. 2011;2011:623924.","journal-title":"ISRN Hematol."},{"issue":"16","key":"805_CR8","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"805_CR9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/leu.2012.321","volume":"27","author":"S Kim","year":"2013","unstructured":"Kim S, Yoon S, Suzuki R, et al. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia. 2013;27(6):1394\u20137.","journal-title":"Leukemia"},{"issue":"3191","key":"805_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"Otto Warburg","year":"1956","unstructured":"Warburg Otto. On the origin of cancer cells. Science. 1956;123(3191):309\u201314. https:\/\/doi.org\/10.1126\/science.123.3191.309.","journal-title":"Science"},{"key":"805_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"S Lunt","year":"2011","unstructured":"Lunt S, Vander HM. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Bi. 2011;27:441\u201364.","journal-title":"Annu Rev Cell Dev Bi"},{"issue":"1","key":"805_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/iub.573","volume":"64","author":"A Halestrap","year":"2012","unstructured":"Halestrap A. The monocarboxylate transporter family\u2013Structure and functional characterization. IUBMB Life. 2012;64(1):1\u20139.","journal-title":"IUBMB Life"},{"issue":"2","key":"805_CR13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/iub.572","volume":"64","author":"A Halestrap","year":"2012","unstructured":"Halestrap A, Wilson M. The monocarboxylate transporter family\u2013role and regulation. IUBMB Life. 2012;64(2):109\u201319.","journal-title":"IUBMB Life"},{"issue":"10","key":"805_CR14","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.bbamcr.2016.03.013","volume":"1863","author":"J P\u00e9rez-Escuredo","year":"2016","unstructured":"P\u00e9rez-Escuredo J, Van H\u00e9e V, Sboarina M, et al. Monocarboxylate transporters in the brain and in cancer. Biochim Biophys Acta. 2016;1863(10):2481\u201397.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"805_CR15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/PGP.0b013e31817b5b40","volume":"27","author":"C Pinheiro","year":"2008","unstructured":"Pinheiro C, Longatto-Filho A, Ferreira L, et al. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol. 2008;27(4):568\u201374.","journal-title":"Int J Gynecol Pathol"},{"key":"805_CR16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1476-4598-11-76","volume":"11","author":"J Ho","year":"2012","unstructured":"Ho J, de Moura M, Lin Y, et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer. 2012;11:76.","journal-title":"Mol Cancer"},{"issue":"12","key":"805_CR17","first-page":"3930","volume":"118","author":"P Sonveaux","year":"2008","unstructured":"Sonveaux P, V\u00e9gran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118(12):3930\u201342.","journal-title":"J Clin Invest"},{"issue":"12","key":"805_CR18","first-page":"3835","volume":"118","author":"G Semenza","year":"2008","unstructured":"Semenza G. Tumor metabolism: cancer cells give and take lactate. J Clin Invest. 2008;118(12):3835\u20137.","journal-title":"J Clin Invest"},{"issue":"12","key":"805_CR19","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1158\/1535-7163.MCT-13-1091","volume":"13","author":"B Bola","year":"2014","unstructured":"Bola B, Chadwick A, Michopoulos F, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014;13(12):2805\u201316.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"805_CR20","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-16-2686","volume":"77","author":"M Beloueche-Babari","year":"2017","unstructured":"Beloueche-Babari M, Wantuch S, Casals Galobart T, et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 2017;77(21):5913\u201324.","journal-title":"Cancer Res"},{"issue":"41","key":"805_CR21","doi-asserted-by":"crossref","first-page":"69219","DOI":"10.18632\/oncotarget.18215","volume":"8","author":"N Curtis","year":"2017","unstructured":"Curtis N, Mooney L, Hopcroft L, et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt\u2019s lymphoma anti-tumor activity. Oncotarget. 2017;8(41):69219\u201336.","journal-title":"Oncotarget"},{"issue":"6","key":"805_CR22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/cancers12061703","volume":"12","author":"M Braga","year":"2020","unstructured":"Braga M, Kaliszczak M, Carroll L, et al. Tracing nutrient flux following monocarboxylate transporter-1 inhibition with AZD3965. Cancers. 2020;12(6):1703.","journal-title":"Cancers"},{"issue":"6","key":"805_CR23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41416-019-0717-x","volume":"122","author":"M Beloueche-Babari","year":"2020","unstructured":"Beloueche-Babari M, Casals Galobart T, Delgado-Goni T, et al. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Brit J Cancer. 2020;122(6):895\u2013903.","journal-title":"Brit J Cancer"},{"issue":"7","key":"805_CR24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3324\/haematol.2016.163030","volume":"102","author":"R Noble","year":"2017","unstructured":"Noble R, Bell N, Blair H, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102(7):1247\u201357.","journal-title":"Haematologica"},{"issue":"3","key":"805_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13402-019-00426-2","volume":"42","author":"J Afonso","year":"2019","unstructured":"Afonso J, Pinto T, Sim\u00f5es-Sousa S, et al. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma. Cell Oncol. 2019;42(3):303\u201318.","journal-title":"Cell Oncol"},{"issue":"7757","key":"805_CR26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang F, Jan\u00e9-Valbuena J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503\u20138.","journal-title":"Nature"},{"issue":"27","key":"805_CR27","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"B Cheson","year":"2014","unstructured":"Cheson B, Fisher R, Barrington S, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"9","key":"805_CR28","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1093\/cercor\/bhy254","volume":"29","author":"S Gao","year":"2019","unstructured":"Gao S, Zhang T, Jin L, et al. CAPON is a critical protein in synaptic molecular networks in the prefrontal cortex of mood disorder patients and contributes to depression-like behavior in a mouse model. Cereb Cortex. 2019;29(9):3752\u201365.","journal-title":"Cereb Cortex"},{"issue":"25","key":"805_CR29","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756\u201367.","journal-title":"Blood"},{"key":"805_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-pathol-020117-043821","volume":"13","author":"M Pizzi","year":"2018","unstructured":"Pizzi M, Margolskee E, Inghirami G. Pathogenesis of peripheral T Cell lymphoma. Annu Rev Pathol. 2018;13:293\u2013320.","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"805_CR31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djw248","volume":"109","author":"C Casulo","year":"2017","unstructured":"Casulo C, O\u2019Connor O, Shustov A, et al. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. J Natl Cancer Inst. 2017;109(2):248.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"805_CR32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11899-016-0353-y","volume":"11","author":"A Phan","year":"2016","unstructured":"Phan A, Veldman R, Lechowicz MJ. T-cell lymphoma epidemiology: the known and unknown. Curr Hematol Malig Rep. 2016;11(6):492\u2013503.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"805_CR33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13045-020-01006-w","volume":"13","author":"K Izykowska","year":"2020","unstructured":"Izykowska K, Rassek K, Korsak D, Przybylski GK. Novel targeted therapies of T cell lymphomas. J Hematol Oncol. 2020;13(1):176.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"805_CR34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","volume":"19","author":"Y Ito","year":"2019","unstructured":"Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19(3):197\u2013209.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"805_CR35","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","volume":"58","author":"D Sborov","year":"2017","unstructured":"Sborov D, Canella A, Hade E, et al. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia Lymphoma. 2017;58(10):2310\u20138.","journal-title":"Leukemia Lymphoma"},{"issue":"8","key":"805_CR36","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","volume":"20","author":"M Bagot","year":"2019","unstructured":"Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160\u201370.","journal-title":"Lancet Oncol"},{"issue":"8","key":"805_CR37","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"27","author":"S Ansell","year":"2021","unstructured":"Ansell S, Maris M, Lesokhin A, et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27(8):2190\u20139.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"805_CR38","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp M, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024\u201331.","journal-title":"Blood"},{"issue":"3","key":"805_CR39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","volume":"183","author":"A Seto","year":"2018","unstructured":"Seto A, Beatty X, Lynch J, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Brit J Haematol. 2018;183(3):428\u201344.","journal-title":"Brit J Haematol"},{"issue":"6","key":"805_CR40","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/cas.14906","volume":"112","author":"H Kawai","year":"2021","unstructured":"Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021;112(6):2426\u201335.","journal-title":"Cancer Sci"},{"issue":"3","key":"805_CR41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/dmd.119.087338","volume":"48","author":"S Pusalkar","year":"2020","unstructured":"Pusalkar S, Zhou X, Li Y, et al. Biotransformation pathways and metabolite profiles of oral [C]Alisertib (MLN8237), an investigational aurora a kinase inhibitor, in patients with advanced solid tumors. Drug Metab Dispos. 2020;48(3):217\u201329.","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"805_CR42","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","volume":"134","author":"L Lindahl","year":"2019","unstructured":"Lindahl L, Willerslev-Olsen A, Gjerdrum L, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134(13):1072\u201383.","journal-title":"Blood"},{"key":"805_CR43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","volume":"33","author":"V Payen","year":"2020","unstructured":"Payen V, Mina E, Van H\u00e9e V, Porporato P, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48\u201366.","journal-title":"Mol Metab"},{"issue":"3","key":"805_CR44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/0008-5472.CAN-13-2034","volume":"74","author":"J Doherty","year":"2014","unstructured":"Doherty J, Yang C, Scott K, et al. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 2014;74(3):908\u201320.","journal-title":"Cancer Res"},{"issue":"6","key":"805_CR45","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.celrep.2014.11.025","volume":"9","author":"G Baek","year":"2014","unstructured":"Baek G, Tse Y, Hu Z, et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 2014;9(6):2233\u201349.","journal-title":"Cell Rep"},{"key":"805_CR46","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1471-2407-11-312","volume":"11","author":"N P\u00e9rtega-Gomes","year":"2011","unstructured":"P\u00e9rtega-Gomes N, Vizca\u00edno J, Miranda-Gon\u00e7alves V, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 2011;11:312.","journal-title":"BMC Cancer"},{"key":"805_CR47","doi-asserted-by":"crossref","first-page":"427694","DOI":"10.1155\/2010\/427694","volume":"2010","author":"C Pinheiro","year":"2010","unstructured":"Pinheiro C, Reis R, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol. 2010;2010:427694.","journal-title":"J Biomed Biotechnol."},{"issue":"7","key":"805_CR48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2559.2010.03560.x","volume":"56","author":"C Pinheiro","year":"2010","unstructured":"Pinheiro C, Albergaria A, Paredes J, et al. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology. 2010;56(7):860\u20137.","journal-title":"Histopathology"},{"issue":"2","key":"805_CR49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/neuonc\/nos298","volume":"15","author":"V Miranda-Gon\u00e7alves","year":"2013","unstructured":"Miranda-Gon\u00e7alves V, Honavar M, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 2013;15(2):172\u201388.","journal-title":"Neuro Oncol"},{"issue":"1","key":"805_CR50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2013.08.042","volume":"342","author":"Z Zhao","year":"2014","unstructured":"Zhao Z, Wu M, Zou C, et al. Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-\u03baB pathway. Cancer Lett. 2014;342(1):150\u20138.","journal-title":"Cancer Lett"},{"issue":"1","key":"805_CR51","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1038\/s41598-021-84019-w","volume":"11","author":"M Leu","year":"2021","unstructured":"Leu M, Kitz J, Pilavakis Y, et al. Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome. Sci Rep-UK. 2021;11(1):4578.","journal-title":"Sci Rep-UK"},{"issue":"5","key":"805_CR52","first-page":"5727","volume":"14","author":"Y Ruan","year":"2017","unstructured":"Ruan Y, Zeng F, Cheng Z, Zhao X, Fu P, Chen H. High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma. Oncol Lett. 2017;14(5):5727\u201334.","journal-title":"Oncol Lett"},{"key":"805_CR53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omto.2020.06.012","volume":"18","author":"T Kuo","year":"2020","unstructured":"Kuo T, Huang K, Yang S, et al. Monocarboxylate Transporter 4 Is a Therapeutic Target in Non-small Cell Lung Cancer with Aerobic Glycolysis Preference. Mol Ther-Oncolytics. 2020;18:189\u2013201.","journal-title":"Mol Ther-Oncolytics"},{"key":"805_CR54","doi-asserted-by":"crossref","unstructured":"International_Non-Hodgkin's_Lymphoma_Prognostic_Factors_Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-94.","DOI":"10.1056\/NEJM199309303291402"},{"key":"805_CR55","first-page":"1113","volume":"28","author":"K Szczuraszek","year":"2008","unstructured":"Szczuraszek K, Mazur G, Jele\u0144 M, Dziegiel P, Surowiak P, Zabel M. Prognostic significance of Ki-67 antigen expression in non-Hodgkin\u2019s lymphomas. Anticancer Res. 2008;28:1113\u20138.","journal-title":"Anticancer Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00805-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T03:09:35Z","timestamp":1646276975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00805-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":55,"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00805-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1002043\/v1","asserted-by":"object"}]},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"23 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}